PaxVax appoints COO Farzan as president; Immunovaccine gets green light for RSV vaccine trial;

> PaxVax has appointed COO Nima Farzan as company president and COO. Release

> Takeda's vaccines president Rajeev Venkayya says his company is evaluating potential candidates in its pipeline that might have an impact on the Ebola virus. Interview

> Health Canada has cleared Immunovaccine to begin a Phase I trial of its RSV vaccine candidate. Release

> Two patients have been on Aduro Biotech's cancer vaccine combo regimen for more than two years and have snown no evidence of cumulative toxicity. Release

Half of girls ages 11-12, the age the CDC recommends, receive the HPV vaccine. Report

And Finally... A new study confirms long-held speculation that anti-vaccine sentiment can concentrate in communities, increasing the risk of outbreaks. Report

Suggested Articles

Having struck two COVID-19 vaccine supply deals already, EU officials are in discussions with Novavax, as well.

With its phase 3 trial moving right along, Moderna is expecting efficacy data in November—likely after Pfizer and BioNTech, but before everyone else.

BioNTech expects a quick turnaround once the transaction closes and plans to produce up to 250 million doses of BNT162b2 in the first half of 2021.